The Report “EpiCast Report Amyotrophic
Lateral Sclerosis – Epidemiology Forecast to 2023″ by Globaldata Group is now
available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “EpiCast Report Amyotrophic Lateral
Sclerosis – Epidemiology Forecast to 2023″ in subject line and your contact
details to purchase this report or get your questions answered.
Epidemiologists forecast that the diagnosed prevalent cases of ALS in the 7MM will grow by 13.5% over the next decade, from 32,698 diagnosed prevalent cases in 2013 to 37,122 diagnosed prevalent cases in 2023. Throughout the forecast period, the US will have the highest numbers of diagnosed prevalent cases of ALS, followed by Japan.
To develop the epidemiological forecast for the diagnosed prevalent cases of ALS in the 7MM, epidemiologists obtained the diagnosed prevalence data for ALS from peer-reviewed journals and population-based studies in the respective markets and used a consistent methodology to ensure comparability of the results. A major strength of Epidemiological analysis is the use of country-specific studies that provided the diagnosed prevalence of ALS using uniform diagnostic criteria based on the El Escorial criteria or the International Classification of Diseases, Ninth Revision (ICD-9), criteria (ICD-9 code for ALS = 335.2), to allow for a meaningful comparison of the diagnosed prevalent cases of ALS in these markets. Furthermore, the diagnosed prevalent cases of ALS in each of the 7MM were further segmented by age and sex in order to provide a more detailed analysis of the patient population.
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=173921 .
Scope
- The Amyotrophic lateral sclerosis
(ALS) EpiCast Report provides an overview of the risk factors,
comorbidities, and the global and historical trends for ALS in the seven
major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It
includes a 10-year epidemiological forecast for the diagnosed prevalent
cases of ALS segmented by age (=40 years) and sex in these markets.
- The ALS epidemiology report is
written and developed by Mastersand PhD-level epidemiologists.
- The EpiCast Report is in-depth,
high quality, transparent and market-driven, providing expert analysis of
disease trends in the 7MM.
Reasons to buy
- Develop business strategies by
understanding the trends shaping and driving the global ALS market.
- Quantify patient populations in
the global ALS market to improve product design, pricing, and launch
plans.
- Organize sales and marketing
efforts by identifying the sex and age groups that present the best
opportunities for ALS therapeutics in each of the markets covered.
Complete
report is available @ http://www.rnrmarketresearch.com/epicast-report-amyotrophic-lateral-sclerosis-epidemiology-forecast-to-2023-market-report.html .
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global Trends 9
3.3.1 US 10
3.3.2 5EU 11
3.3.3 Japan 13
3.4 Forecast Methodology 13
For further information on “EpiCast Report Amyotrophic Lateral Sclerosis – Epidemiology Forecast to
2023” report OR for any other business research / market intelligence
need on the ‘pharmaceuticals’ market
(http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ),
contact sales@rnrmarketresearch.com /
Call +1 888 391 5441.
About Us:
RnRMarketResearch.com is an online market research
reports library of 250,000+ in-depth studies of over 5000 micro markets. Our
database includes reports by leading publishers from across the globe. We
provide 24/7 online and offline support service to our customers. RnR Market
Research also offers company data, country profiles, trends, information and
analysis on the sector of your interest.
You
can also reach us @
No comments:
Post a Comment
Note: only a member of this blog may post a comment.